Pricing Log in Create free account
Saturday 7 November 2026 Export PGEN’s income statement to Excel — free account

Precigen, Inc.

PGEN Healthcare Biotechnology

Precigen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.7 million, up 146.7% from fiscal 2024.

Revenue
+2,437.6%
EPS
+109.4%
Free cash flow
+140.3%
Total debt
+1.47%

Quarter to September 2026, against a year earlier

4.43 0.21 +4.98%
Market cap
$1.5B
P/E
60.3×
Fwd P/E
20.8×
Dividend yield
—
F-score
3/9
Altman Z
−16.93
Beneish M
−7.67
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.02
Sold, $m 32.50
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — 1 — — —
Sell 2 — — 1 — 5 3 1 5 — — —
Insider Ownership 54.15%

Capital & Financial Ratios $m

Size
Market Cap 1,510.00
Revenue ttm 156.94
Net income ttm 24.41
Free cash flow ttm (74.32)
Net debt Q 48.19
Valuation
P/E 60.27 (above 35: high)
Forward P/E 20.80
Price / sales 10.11 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 18.94 (above 6: high)
Financial health
Current ratio Q 5.58 (at or above 1.5: strong)
Debt / equity Q 1.12
Interest coverage Q 12.90
Growth
Revenue growth Q +2,437.58% (above 0%: growing)
Operating income growth Q +212.09% (above 0%: growing)
EPS, this year +117.15% (at or above 15%: strong)
EPS, next year A +162.77% (at or above 15%: strong)
Revenue, next year A +2,334.94% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +2.40%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 10.5×, against a ten-year median of 13.8×; over the ten years it ranged from −108× in 2022 to 24,282× in 2021.
P/S against its own 10 years 28.64%
10-year low 10-year high
P/B against its own 10 years 86.09%
10-year low 10-year high
EV/Sales against its own 10 years 34.04%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 63 98 98 46
Receivables 2 1 4 97
Inventory — — 10 23
Other — — — —
69 102 115 172
2023 2024 2025 Q'26
Payables 2 4 12 7
ST’ Debt — — — —
Other 5 3 2 —
23 22 37 31

Compound Annual Growth %

10y 5y 3y
Sales (25.07%) (21.26%) (28.87%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (29.66%) (20.82%) (45.08%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 0.09 Actual 0.08

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −0.10 −0.01 Beat by 0.09
Q1 FY26 −0.03 −0.02 Beat by 0.01
Q2 FY26 −0.02 0.05 Beat by 0.07
Q3 FY26 0.09 0.08 Miss by 0.01
Q4 FY26 0.13 — Reports 24 March 2027

EPS $

Mar Jun Sep Dec Year
’26 (0.02) 0.05 0.08 — —
’25 (0.18) (0.09) (1.06) (0.07) (1.37)
’24 (0.10) (0.23) (0.09) (0.06) (0.47)
’23 (0.10) (0.08) (0.08) (0.13) (0.39)
’22 (0.10) (0.09) 0.44 (0.11) 0.14
’21 (0.09) (0.10) (0.15) (0.13) (0.47)
’20 (0.35) (0.26) (0.18) (0.23) (1.02)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 23 55 74 — —
’25 1 1 3 5 10
’24 1 1 1 1 4
’23 2 2 1 1 6
’22 6 3 17 2 27
’21 25 4 3 (17) 14
’20 30 30 24 (52) 32
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (44) (18) 12 — —
’25 (16) (19) (29) (23) (88)
’24 (14) (23) (23) (8) (68)
’23 (18) (16) (17) (16) (67)
’22 (19) (7) (24) (15) (65)
’21 (16) (8) (17) (15) (56)
’20 (28) (14) (19) (16) (77)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (44) (18) 11 — —
’25 (17) (20) (29) (23) (90)
’24 (18) (25) (24) (9) (77)
’23 (19) (16) (17) (17) (68)
’22 (20) (8) (25) (15) (69)
’21 (15) (9) (19) (17) (60)
’20 (30) (15) (20) (13) (78)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.5
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 191 219 151 91 32 14 27 6 4 10 157 (28.2%) 236 437 513 +275.4%
Gross margin, % 67.72 71.89 58.54 32.32 83.20 59.73 76.44 1.70 (8.71) 50.20 91.42 (17.5) pt
EBT (194) (78) (396) (171) (105) (111) (80) (96) (128) (251) 25 +2.9%
EBT margin, % (101.69) (35.71) (261.88) (188.78) (326.72) (777.79) (297.17) (1,547.98) (3,261.86) (2,588.18) 15.68 (2,486.5) pt
Net income (190) (127) (515) (324) (171) (92) 28 (96) (126) (251) 24 +3.1%
Per share, $
Per share, $ Revenue 1.62 1.83 1.17 0.59 0.19 0.07 0.13 0.03 0.01 0.03 0.44 (35.6%)
Earnings (1.58) (0.98) (3.93) (2.09) (1.02) (0.47) 0.14 (0.39) (0.47) (1.37) 0.07 (1.6%)
Cash flow (0.42) (0.86) (0.96) (0.88) (0.46) (0.28) (0.32) (0.27) (0.25) (0.28) (0.20) (4.3%)
Capex (0.27) (0.38) (0.30) (0.24) (0.01) (0.02) (0.02) (0.01) (0.03) (0.01) 0.00 (33.9%)
Free cash flow (0.68) (1.24) (1.26) (1.12) (0.47) (0.30) (0.35) (0.28) (0.29) (0.29) (0.21) (9.2%)
Book value 4.82 4.55 2.92 0.47 0.40 0.54 0.63 0.48 0.25 0.07 0.23 (37.8%)
Shares, m 118 120 130 154 167 198 200 245 268 313 346 +11.4%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 10.55 0.00 0.00 0.00 60.27 1.1
P/S 15.31 7.37 5.60 9.31 53.27 51.43 11.02 55.39 76.40 135.09 10.11 42.0
P/B 5.13 2.96 2.24 11.78 25.37 6.83 2.35 2.91 7.79 62.56 18.94 13.0
EV/Sales 14.07 7.03 5.53 10.89 55.51 56.42 9.20 48.51 56.55 136.04 10.51 40.0
EV/FCF (33.43) (10.37) (5.11) (5.70) (22.75) (13.41) (3.57) (4.42) (2.89) (14.67) (22.19) (11.6)
Cash, $m
Cash, $m Operating cash flow (49) (104) (124) (136) (77) (56) (65) (67) (68) (88) (73) +6.7%
Capex (31) (45) (39) (37) (1) (4) (4) (1) (9) (2) (1) (26.4%)
Free cash flow (80) (149) (164) (173) (78) (60) (69) (68) (77) (90) (74) +1.2%
Balance, $m
Balance, $m Working capital 221 74 224 112 107 122 40 46 81 78 141 (10.9%)
Net debt (236) (73) (12) 143 72 71 (49) (63) (98) (5) 48 (35.3%)
Shareholders’ equity 569 547 379 72 67 107 126 118 67 21 84 (30.7%)
Returns, %
Returns, % ROA (19.33) (13.03) (65.17) (55.01) (44.27) (27.33) 9.84 (52.26) (85.20) (285.69) 12.73 (266.4) pt
ROIC (23.49) (12.67) (62.96) (48.56) (38.83) (32.17) (61.32) (112.05) 0.00 (425.63) 15.93 (402.1) pt
ROE (29.29) (20.97) (110.09) (143.12) (245.56) (105.62) 24.24 (78.37) (160.80) (1,446.02) 38.84 (1,416.7) pt
People
People Employees 935 1,006 979 857 194 191 33 202 143 160 — (17.8%)
Revenue/emp, $m 0.20 0.22 0.15 0.11 0.16 0.07 0.82 0.03 0.03 0.06 — (12.6%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026

Precigen, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
BRVE Braveheart Bio, Inc. $1.6B — — — n/m — — 0.00% Compare
NTLA Intellia Therapeutics, Inc. $1.6B — (loss-making) — (loss-making) −48.03% (below 0%: shrinking) n/m −11.05% (below 0%: shrinking) 100.00% (1,707.73%) Compare
RARE Ultragenyx Pharmaceutical Inc. $1.5B — (loss-making) — (loss-making) +8.13% (above 0%: growing) n/m +12.50% (above 0%: growing) 81.50% (63.58%) Compare
NBTX Nanobiotix S.A. - Sponsored ADR $1.5B — (loss-making) — −71.69% (below 0%: shrinking) n/m −177.26% (below 0%: shrinking) 0.00% 0.00% Compare
PGEN Precigen, Inc. $1.5B 60.3× 32.2× +2,437.58% (above 0%: growing) n/m +140.34% (above 0%: growing) 91.22% 52.13%
NUVB Nuvation Bio Inc. $1.5B — (loss-making) — (loss-making) +242.61% (above 0%: growing) n/m +34.07% (above 0%: growing) 73.46% (93.90%) Compare
ADRX ADARx Pharmaceuticals, Inc. $1.5B — — — — — — — Compare
IMCR Immunocore Holdings PLC Sponsored ADR $1.5B — (loss-making) — (loss-making) −1.42% (below 0%: shrinking) n/m +440.97% (above 0%: growing) 99.34% (13.31%) Compare
QURE uniQure N.V. $1.5B — (loss-making) — (loss-making) +40.39% (above 0%: growing) n/m +27.66% (above 0%: growing) 95.46% (1,019.63%) Compare
Median of peers $1.5B — — +3.35% — +20.08% 88.48% (63.58%)

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 30 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 5.35m 18.57m 40.98
2024 5.43m 4.61m 20.44
2023 3.72m 3.73m 24.45
2022 3.50m (1.09m) 27.74
2021 2.52m (16.11m) 67.70

Ownership

Directors and executive officers, together 41.40%
RJ Kirk and Affiliates 35.90%
Patient Capital Management, LLC 10.10%
William H. Miller III 9.60%
Ares Trading SA 5.80%
Point72 Asset Management, L.P. 5.20%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Precigen, Inc. (PGEN) Latest News

5 Nov

Impact 4 · · The Motley Fool transcript
Impact 4 · · Stocktwits
Impact 4 · · GuruFocus.com
Impact 3 · · MarketBeat transcript

4 Nov

Impact 4 · · PR Newswire

2 Nov

Impact 4 · · TIKR
Impact 3 · · Zacks
Impact 3 · · Stocktwits

30 Oct

Impact 4 · · Stocktwits

28 Oct

Impact 3 · · PR Newswire

19 Oct

Impact 3 · · Simply Wall St.

12 Oct

Impact 4 · · Insider Monkey

5 Oct

Impact 4 · · Zacks

1 Oct

Impact 3 · · Zacks

28 Sep

Impact 3 · · Insider Monkey

26 Sep

Impact 4 · · Simply Wall St.

25 Sep

Impact 4 · · Simply Wall St.

24 Sep

Impact 4 · · Zacks
Impact 3 ·

21 Sep

Impact 4 · · PR Newswire

16 Sep

Impact 4 ·

15 Sep

Impact 5 ·

10 Sep

Impact 4 ·

7 Sep

Impact 3 ·

3 Sep

Impact 4 ·

28 Aug

Impact 3 ·

25 Aug

Impact 4 ·

12 Aug

Impact 4 ·

11 Aug

Impact 3 · · The Motley Fool transcript

5 Aug

Impact 3 · · Moby transcript
stockrow.com/PGEN · Data as of Nov 6, 2026 · For information only; not investment advice. · © 2026 stockrow.com